MSI1 interacts with AGO2 in the cytosol and promote tumor growth. (A) Schematic illustration presenting the experimental design of xenograft orthotropic tumor model. SCID mice were orthotopically transplanted with 05MG/Flag-control, 05MG/MSI1-wt, 05MG/MSI1-NES-mut, or 05MG/MSI1-NLS-mut GFP cells. Twenty days after transplantation, mice were administered 3 times with 2-day interval of Cisplatin (20 mg/kg) or PBS via tail-vein injection. (B) Xenograft tumors were excised 20 days after Cisplatin treatment. Representative images of GFP-positive tumors are shown. N = 6, **P < 0.05. (C) Xenograft orthotropic tumor tissue were sectioned and subjected to IHC to evaluate Flag-tagged tumor, NF2, p53, p21, cyclinD1, CDK4 and ki67 expression levels. (D) Tumors tissues (five of each group) were harvested and homogenized. Whole-tumor lysates were analyzed by qPCR. (E) Co-immunoprecipitation of endogenous AGO2 with Flag-tagged MSI1 using Flag antibody in 05MG/MSI1-WT, 05MG/MSI1-NES-mut, and 05MG/MSI1-NLS-mut xenograft tumors tissues.